ZEO Scientifix Inc (QB) (ZEOX) Börsenkurse

Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will...

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

-- Three medical experts will join members of Syros’ leadership team to provide an overview of HR-MDS patient management, perspectives on the current and future treatment landscape, and the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update

– Passed Interim Futility Analysis of the Primary Endpoint in Phase 3 SELECT-MDS-1 Trial of Tamibarotene; Pivotal CR Data Expected by Mid-4Q 2024; Company to Host HR-MDS-focused Webcast Event...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Syros to Participate in Upcoming Investor Conferences

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company...

Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will...

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the...